RxDoctor Payments Data

David Truluck, MD

Interventional Cardiology · Myrtle Beach, SCNPI 1194714279

Payments from drug & device makers

$855in general payments, 2019–2025

Across 34 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$141
  • Amgen$130
  • Recor Medical Inc$122
  • Atricure, Inc.$74
  • Shockwave Medical, Inc$61
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54
  • plus $274 from 10 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 0th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$303,686
Medicare patients
1,298
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$382,923
EntrestoSacubitril/Valsartan134$198,722
XareltoRivaroxaban86$102,460
FarxigaDapagliflozin Propanediol60$82,793
MultaqDronedarone Hcl33$56,382
Repatha SureclickEvolocumab36$31,522
Praluent PenAlirocumab12$17,094
Repatha SyringeEvolocumab11$11,749
Rosuvastatin Calcium427$9,102
Metoprolol Succinate441$7,664
ClopidogrelClopidogrel Bisulfate579$7,557
Dofetilide34$5,029
Atorvastatin Calcium287$3,811
Dabigatran EtexilateDabigatran Etexilate Mesylate12$2,611
Diltiazem 24hr Er (La)Diltiazem Hcl22$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$382,923295 claims
NovartisEntresto$21$198,722134 claims
AstraZenecaFarxiga$14$82,79360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →